GADD45β Loss Ablates Innate Immunosuppression in Cancer

Daniela Verzella, Jason Bennett, Mariafausta Fischietti, Anil K. Thotakura, Camilla Recordati, Fabio Pasqualini, Daria Capece, Davide Vecchiotti, Daniel D'Andrea, Barbara Di Francesco, Marcella De Maglie, Federica Begalli, Laura Tornatore, Salvatore Papa, Toby Lawrence, Stuart J. Forbes, Antonio Sica, Edoardo Alesse, Francesca Zazzeroni, Guido Franzoso

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

T-cell exclusion from the tumor microenvironment (TME) is a major barrier to overcoming immune escape. Here, we identify a myeloid-intrinsic mechanism governed by the NF-κB effector molecule GADD45β that restricts tumor-associated inflammation and T-cell trafficking into tumors. In various models of solid cancers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells restored activation of proinflammatory tumor-associated macrophages (TAM) and intratumoral immune infiltration, thereby diminishing oncogenesis. Our results provide a basis to interpret clinical evidence that elevated expression of GADD45B confers poor clinical outcomes in most human cancers. Furthermore, they suggest a therapeutic target in GADD45β for reprogramming TAM to overcome immunosuppression and T-cell exclusion from the TME.
Original languageEnglish
Pages (from-to)1275-1292
Number of pages18
JournalCancer Research
Volume78
Issue number5
Early online date26 Dec 2017
DOIs
Publication statusPublished - Mar 2018
Externally publishedYes

Fingerprint Dive into the research topics of 'GADD45β Loss Ablates Innate Immunosuppression in Cancer'. Together they form a unique fingerprint.

  • Cite this

    Verzella, D., Bennett, J., Fischietti, M., Thotakura, A. K., Recordati, C., Pasqualini, F., ... Franzoso, G. (2018). GADD45β Loss Ablates Innate Immunosuppression in Cancer. Cancer Research, 78(5), 1275-1292. https://doi.org/10.1158/0008-5472.CAN-17-1833